Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Manufacturing & supply

XORTX finishes making trial batches of oxypurinol gout tablet, turns to regulators

The Canadian drugmaker has produced and packed the study material for XORLO, its gout candidate, clearing a practical hurdle before it seeks permission to dose patients.

16 Nov 2026 · XORTX Therapeutics Inc. XRTX · Company news

XORTX Therapeutics said on 16 November 2026 that the drug supply for its XRX-OXY-102 study of XORLO, an oxypurinol tablet for gout, has been made and packaged. Having the material in hand removes a manufacturing dependency before the study can go ahead, though the company has not yet said when patients will be dosed.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): XORTX Therapeutics Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Manufacturing & supplyAll →